Sugi Predict

Sugi Predict / Compounds / SCHEMBL1324522

SCHEMBL1324522

SCHEMBL1324522

O=C(O)c1cc(Cl)c2ccnn2c1-c1cccc(F)c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4C Q9H3R0 2/20 0.43
▸ KDM5A P29375 1/20 0.43
▸ KDM5B Q9UGL1 1/20 0.43
▸ KMO O15229 2/20 0.40
▸ DCLRE1B Q9H816 1/20 0.40
▸ NR4A1 P22736 1/20 0.40
▸ NR4A2 P43354 1/20 0.40
▸ NR4A3 Q92570 1/20 0.40
▸ PDE4B Q07343 2/20 0.39
▸ FABP3 P05413 1/20 0.39
▸ FABP4 P15090 1/20 0.39
▸ KDM4E B2RXH2 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ GPR35 Q9HC97 2/20 0.38
▸ DHODH Q02127 2/20 0.38
▸ PIN1 Q13526 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ MDM2 Q00987 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1324832 0.89 PDE4B (0.39) KDM4CKDM5AKDM5BKMOPDE4B
SCHEMBL1324537 0.86 MAPK14 (0.41) KDM4CKDM5AKDM5BNR4A2PDE4B
SCHEMBL12285065 0.85 GRIN2B (0.35) KDM4CKDM5AKDM5BPDE4BKDM4E
SCHEMBL1325440 0.82 TRPM8 (0.45) KDM4CKDM5AKDM5BPDE4B
SCHEMBL1325539 0.79 DCLRE1B (0.40) KDM4CKMODCLRE1BNR4A1NR4A2
SCHEMBL18817093 0.76 GRIN2B (0.40) KDM4CKMODCLRE1BFABP3FABP4
SCHEMBL1325820 0.76 PTGS2 (0.33) KDM4CKDM5AKDM5BPDE4BKDM4E
SCHEMBL1324655 0.76 KMO (0.41) KDM4CKDM5AKDM5BKMODCLRE1B
SCHEMBL1325462 0.72 DCLRE1B (0.43) KDM4CKDM5AKDM5BKMODCLRE1B
SCHEMBL18817355 0.70 CYP11B2 (0.44) NR4A2PDE4BKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9193721-B2 Fused derivatives as PI3Kδ inhibitors INCYTE HOLDINGS CORPORATION (US) 2015-11-24 — — US disclosed
US-9193721-B2 Fused derivatives as PI3Kδ inhibitors INCYTE HOLDINGS CORPORATION (US) 2015-11-24 — — US disclosed
US-9193721-B2 Fused derivatives as PI3Kδ inhibitors INCYTE HOLDINGS CORPORATION (US) 2015-11-24 — — US disclosed
EP-2558463-A1 FUSED DERIVATIVES AS I3 INHIBITORS Incyte Corporation (US) 2013-02-20 — — EP disclosed
US-20110281884-A1 FUSED DERIVATIVES AS PI3KDELTA INHIBITORS INCYTE CORPORATION 2011-11-17 — — US disclosed
US-20110281884-A1 FUSED DERIVATIVES AS PI3KDELTA INHIBITORS INCYTE CORPORATION 2011-11-17 — — US disclosed
WO-2011130342-A1 FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS INCYTE CORPORATION (US) 2011-10-20 — — WO disclosed
WO-2011130342-A1 FUSED DERIVATIVES AS ΡI3Κδ INHIBITORS INCYTE CORPORATION (US) 2011-10-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281884-A1 FUSED DERIVATIVES AS PI3KDELTA INHIBITORS PIK3CD, PIK3CA, PIK3CB KDM4C 3742/4885KDM5A 3452/4885KDM5B 3501/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.